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ABSTRACT
Growth factors, including nerve growth factor (NGF), have been
hypothesized to play a role in resistance to chemotherapeutic
agent-induced apoptosis. Induction by NGF of resistance to
apoptosis is primarily thought to be the result of its binding to
its high-affinity receptor, TrkA. The low-affinity NGF receptor,
p75, has long been thought merely to facilitate NGF binding to
TrkA. However, we have previously shown that the binding of
NGF to its low-affinity receptor, p75, protects neuroblastoma
cells that do not express TrkA against apoptosis induced by
enediyne chemotherapeutic agents. In cells that express both
receptors, it is not clear what determines which receptor is
responsible for the protective effect of NGF. We now show that,
in enediyne-treated SH-SY5Y neuroblastoma transfectants
with native levels of p75 and a low TrkA/p75 ratio (1/100), the
anti-apoptotic effect of NGF requires binding to p75. In con-
trast, in transfectants with native levels of p75 and a high
TrkA/p75 ratio (100/100), NGF treatment prevents enediyne-
induced apoptosis by a mechanism independent of p75 bind-
ing. Treatment of low TrkA/p75 ratio cells with NGF results in
activation and nuclear translocation of NF-B and tyrosine
phosphorylation of TrkA. Analogous treatment of high TrkA/p75
ratio cells results only in phosphorylation of TrkA even though
nuclear factor (NF)-B signaling is not inactive and can be
initiated by other ligands. The ratio of TrkA/p75 in cells that
express both receptors probably contributes to the determina-
tion of which of the two known roles of p75 (i.e., TrkA indepen-
dent or TrkA facilitatory) are responsible for NGF-mediated
protection from enediyne-induced apoptosis.
Several growth factors have recently been found to in-
crease chemotherapeutic resistance of cancer cells (Koutsil-
ieris et al., 1999; Schor, 1999; Sola et al., 1999; Bunn et al.,
2000; Powis et al., 2000; Sezer et al., 2001). In the case of
tumors of the nervous system, nerve growth factor (NGF),
among other neurotrophins, has been implicated in resis-
tance to apoptosis induction (Cortazzo and Schor, 1996;
Schor, 1999; Schor and Saragovi, 1999).
The biological activities of NGF result from its binding to one
or both of its receptors termed TrkA and p75, respectively. This
binding in turn triggers a cascade of cellular signaling events,
the precise nature of which is still the subject of considerable
investigation and controversy (Bono et al., 1999). TrkA, the
high-affinity NGF receptor, is a tyrosine kinase the autophos-
phorylation of which results in initiation of the mitogen-acti-
vated protein kinase (Ulrich et al., 1998), inositol-1,4,5-triphos-
phate, adapter protein Shc, fibroblast growth factor receptor
substrate 2, and other pathways (van der Geer et al., 1996;
Meakin et al., 1999). TrkA is primarily but not exclusively
expressed on cells of neural lineage. In contrast, the signaling
mechanism related to the binding of NGF to its low-affinity
receptor, p75, has only recently begun to be defined. The p75
receptor has variously been found to induce apoptosis when
not bound to NGF (Rabizadeh et al., 1993; Huang et al.,
2000), induce (Kuner and Hertel, 1998; Sedel et al., 1999)
or prevent (Rabizadeh et al., 1993; Cortazzo et al., 1996)
apoptosis when bound to NGF, and mediate neurotrophin
dependence and alter neurotrophin affinity of other neu-
rotrophin receptors when coexpressed with them (Bre-
desen et al., 1998; Ross et al., 1998). Signaling of NGF
through p75 alone is thought to involve the NF-B/cer-
amide pathway (Carter et al., 1996; Dobrowsky and
Carter, 1998; Brann et al., 1999; Coulson et al., 1999).
It is easy to envision the role of p75 as an independent signal
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transducer in cells that express only this receptor and not any
of the Trk family tyrosine kinase receptors (Cortazzo et al.,
1996). Similarly, it is not surprising that the magnitude and
duration of NGF signaling through TrkA is dependent on how
many p75 receptors participate in the enhancement of TrkA
affinity for NGF (Chao et al., 1998; Twiss et al., 1998). This is
especially so because, in addition to enhancing TrkA-NGF af-
finity, p75 is also a functional regulator of TrkA trophic activity
(Maliartchouk and Saragovi, 1997; Saragovi et al., 1998). What
is unexpected and novel is the p75-mediated protective effect of
NGF against enediyne chemotherapeutic agent-induced apo-
ptosis in NGF-independent cells (Cortazzo et al., 1996). This is
in sharp distinction to the proapoptotic effects of p75 alone in
NGF-dependent cells deprived of NGF (Bredesen et al., 1998)
and of NGF through p75 in developing motoneurons in the rat
embryonic spinal cord (Sedel et al., 1999). We now demonstrate
that the ratio of TrkA/p75 in the cell membrane is one deter-
minant of the relative importance of the two alternative signal-
ing pathways triggered by NGF for its negative effect on
enediyne-induced apoptosis.
Materials and Methods
Cells. SY5Y-TrkA (high TrkA/p75) and SY5Y-ET (low TrkA/p75)
cells were the kind gift of Dr. Alonzo Ross (University of Massachusetts
Medical Center, Worcester, MA). These cells were generated by trans-
fection by electroporation of the TrkA expression vector, pIRVCMV-
TrkA, or the corresponding vector lacking the trkA insert, respectively,
into SH-SY5Y cells. Unlike SY5Y-ET cells, SY5Y-TrkA cells overex-
press TrkA. Like native TrkA, the overexpressed product is phosphor-
ylated upon NGF treatment and mediates NGF-induced neurite out-
growth in SY5Y-TrkA cells (Poluha et al., 1995). All cells used in these
studies were demonstrated to be mycoplasma-free using a MycoTect Kit
(Invitrogen, Carlsbad, CA). SY5Y-TrkA and SY5Y-ET cells were cul-
tured in RPMI 1640 medium supplemented with 1% (v/v) glutamine
(200 mM), 10% fetal bovine serum, and 0.4% (v/v) G418 (5 mg/ml) as the
selection antibiotic for these transfectants.
Chemicals and Reagents. Neocarzinostatin (NCS), an enediyne
antineoplastic agent previously demonstrated to induce apoptosis in
SH-SY5Y neuroblastoma cells in culture (Hartsell et al., 1995, 1996),
was obtained from Kayaku Pharmaceuticals Ltd. (Tokyo, Japan).
NCS was stored in powder form at 20°C; a 47 M (0.5 mg/ml)
working stock solution in 0.015 M sodium acetate buffer, pH 5.0, was
stored in the dark at 4°C for up to 2 weeks and diluted with medium
immediately before each experiment. NGF was obtained from Roche
Applied Science (Indianapolis, IN).
Preparation and characterization of the monoclonal antibody
mAbNGF30 were described in our previous publication (Saragovi et al.,
1998). This antibody binds to the p75 binding site of NGF, blocking the
binding of NGF to p75. Monoclonal antibody 5C3, a TrkA-specific NGF
agonist, was prepared as described previously (LeSauteur et al., 1996).
Mouse monoclonal anti-TrkA IgG (Ab-1) was obtained from Calbio-
chem. Rabbit polyclonal anti-p65 IgG, mouse monoclonal anti-phospho-
TrkA IgG (E-6) and rabbit anti-mouse IgG-HRP were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Cy3-conjugated AffiniPure
Goat Anti-rabbit IgG(HL) and Cy2-conjugated AffiniPure Rabbit An-
ti-mouse IgG(HL) were obtained from Jackson ImmunoResearch Lab-
oratories, Inc. (West Grove, PA) and used for fluorescent immunostain-
ing of cells. Geneticin Solution (antibiotic G418), 7-amino-actinomycin
D (7-AAD), and saponin were purchased from Sigma Chemical Corpo-
ration (St. Louis, MO).
Flow Cytometric Analysis. Apoptotic cells were quantified by
flow cytometry considering 7-AAD staining intensity to be propor-
tional to the DNA content (Lecoeur and Gougeon, 1996). In short,
after harvesting, the cells were washed once in PBS and once in
PBS/0.05% saponin, followed by addition of 4 g of 7-AAD in 1 ml of
PBS/saponin to the samples. The cells were incubated at room tem-
perature in the dark for 30 min, and DNA histograms were obtained
using a CellQuest apparatus and CellQuest software (BD Bio-
sciences, San Jose, CA). Data on 104 cells were collected. Electronic
gates were set for viable and apoptotic cells with 2N to 4N DNA and
subnormal DNA content, respectively, and for exclusion of debris.
Percentage of apoptosis was calculated as (number of apoptotic cells
/ number of total cells)  100.
Effects of Blocking p75 Binding of NGF on Its Antiapop-
totic Activity in SY5Y-ET and SY5Y-TrkA Cells. Sister cultures
of SY5Y-ET cells and SY5Y-TrkA cells were treated with a preincu-
bated (15 min) mixture of mAbNGF30 and NGF ([mAbNGF30]:
[NGF]  2:1; final [NGF]  2 nM) from 24 h before through the
completion of the experiment. Twenty-four hours after the addition
of the NGF mixture, the cells were treated for 1 h with NCS at two
different concentrations (3 and 10 nM). Control conditions for this
experiment included cells treated with NGF alone, mAbNGF30
alone, NCS alone, NGF followed by NCS, NGF with mAbNGF30, and
mAbNGF30 followed by NCS. Adherent cells were counted as de-
scribed previously (Hartsell et al., 1995, 1996; Cortazzo et al., 1996),
and flow cytometric and fluorescence microscopic assessments of
percent apoptosis were performed as described above.
Effect of NGF on NF-B Activation in SY5Y-ET and SY5Y-
TrkA Cells. Cells were treated for 2 h with NGF (2 nM) or an
equivalent volume of vehicle. Nuclear extracts were made from these
cells as follows: treated cells were washed twice with ice-cold PBS
and harvested by scraping into fresh PBS. Harvested cells were
washed again with ice-cold PBS, then with 10 mM Tris buffer, pH
7.5, containing 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 0.5
mM PMSF, and 0.1 mM Na3VO4, and then suspended in the same
buffer made 0.1% in Triton X-100. Cells were vortexed gently on ice,
incubated on ice for 10 min, and then centrifuged at 7000 rpm for 5
min at 4°C. The pellet was suspended once again in 20 mM Tris
buffer, pH 7.5, containing 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM
EDTA, 0.5 mM PMSF, 0.5 mM dithiothreitol, 0.1 mM Na3VO4, 0.1%
Triton X-100, and 25% glycerol, and incubated on ice for 20 min. The
mixture was centrifuged at 14,500 rpm for 15 min at 4°C, and the
pellet was discarded. The supernatant (nuclear extract) was diluted
with three volumes of 20 mM Tris buffer, pH 7.5, containing 1.5 mM
MgCl2, 25 mM KCl, 0.2 mM EDTA, 0.5 mM PMSF, 0.5 mM dithio-
threitol, 0.1 mM Na3VO4, and 20% glycerol. Nuclear extracts were
aliquoted (20 l/vial) and frozen until analysis.
Gel Shift Assays. For gel shift analysis, the 32P-labeled double-
stranded NF-B consensus oligonucleotides [sense, 5GGGGAGTT-
GAGGGGACTT-TCCCAGGC3; antisense, 5GGGGGCCTGGGAA-
AGTCCCCTCAACT3 (DNA Synthesis Facility, University of Pitts-
burgh)] were annealed to the nuclear extracts by PCR thermocycling
(85°C, 2 min; 65°C, 15 min; 37°C, 15 min; 22°C, 15 min; 0°C, 15 min).
For supershifts, a subsequent incubation was performed with anti-
bodies to the p65 or p50 components of NF-B (Santa Cruz Biotech-
nology, Inc.). Samples were run (2.5 g of protein/lane) on a 4%
polyacrylamide gel. The gel was dried and subsequently exposed to
X-ray film overnight (4°C) for autoradiographic analysis.
Effects of NGF on Phosphorylation of IB-. SY5Y-ET and
SY5Y-TrkA cells were treated with NGF (2 nM) for 0 to 6 h. Cells
were rinsed with fresh medium and harvested with trypsin. After
washing twice, cells were suspended in radioimmunoprecipitation
assay buffer containing PMSF, aprotinin, and Na3VO4 and was then
homogenized. Homogenates were run on a 10% polyacrylamide gel
(500 g protein/lane) and transferred to a Trans-Blot Pure Nitrocel-
lulose Membrane (0.45 m; Bio-Rad) using a Bio-Rad Trans-Blot
apparatus. Staining was performed using antibodies to IB-, phos-
pho-IB-, and -actin at 20°C for 2 h, then washed, and incubated
with horseradish peroxidase-conjugated secondary antibodies for
1 h. Staining with nonimmune serum in place of primary antibody
served as a negative control in these studies. The membrane was
finally washed and developed with Western Blotting Chemilumines-
cence Luminol Reagent (Santa Cruz Biotechnology) following the
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manufacturer’s instructions. Optical scanning of the membranes was
performed using a Optiscan optical scanner (Bio-Rad, Hercules, CA).
Western Blot and Immunohistochemical Demonstration of
Phosphorylation of TrkA and Translocation of p65 in
SY5Y-ET and SY5Y-TrkA Cells. At the indicated time points after
incubation with 40 nM NGF, SY5Y-ET, and SY5Y-TrkA cells were
lysed in radioimmunoprecipitation assay buffer (10 mM Tris, pH 8,
150 mM NaCl, 0.1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1%
SDS, 1 mM PMSF, 4 g/ml aprotinin, and 1 mM sodium orthovana-
date). Subsequently the protein concentrations of the lysates were
estimated using the Bio-Rad protein assay (Bio-Rad) with bovine
serum albumin as a standard. An aliquot of each lysate containing
150 g of protein was loaded onto each lane and electrophoresed on
a 15% SDS-polyacrylamide gel, followed by blotting on a nitrocellu-
lose membrane (Bio-Rad). After blotting, nonspecific binding was
blocked with 5% nonfat dry milk in PBS and the membrane was
incubated with either anti-TrkA or anti-phospho-TrkA antibodies
(primary antibody) diluted in 5% nonfat dry milk in PBS at 20°C for
2 h. The blot was then developed with Western Blotting Chemilumi-
nescence Luminol Reagent (Santa Cruz Biotechnology), as described
above for IB- blots. For SY5Y-TrkA cell lysates, the blot was
developed for 1 min. For SY5Y-ET cell lysates, known to contain
100-fold less TrkA than SY5Y-TrkA cell lysates (Poluha et al., 1995),
the blot was developed for 10 min. In all cases, the same blot was
stained for TrkA, stripped using standard methods, and restained for
phospho-TrkA using the same development time as for TrkA.
For immunohistochemical staining, SY5Y-TrkA and SY5Y-ET cells
were grown on glass coverslips in six-well tissue culture plates. The
cells were incubated with NGF and/or NCS, washed three times with
PBS, fixed in 95% ethanol for 20 min, and washed three more times
with PBS. The cells were then permeabilized by incubation in 2% Triton
X-100 for 30 min followed by three PBS washes. After blocking of
nonspecific staining (0.5% bovine serum albumin  2% horse serum in
PBS; 10 min), the cells were incubated for 2 h at 37°C with the appro-
priate primary antibody (anti-p65, anti-TrkA, or anti-p-TrkA) and then
with a 1:100 dilution of goat anti-rabbit Cy3 immunoconjugate or rabbit
anti-mouse Cy2 immunoconjugate followed by three additional washes
(10 min each) with PBS. Coverslips were removed from the wells and
mounted with Gelvatol [15.3% (w/v) polyvinyl alcohol, 33% (v/v) glycer-
ol] onto glass microscope slides. A Zeiss light microscope equipped for
epifluorescent illumination was used for examining these preparations.
Nonspecific immunostaining (negative control) was assessed by subject-
ing sister cultures to this same procedure minus treatment with the
primary antibody.
Statistical Methods. For studies involving the comparison of mul-
tiple samples, statistical significance was assessed by one-way ANOVA
followed by Fisher’s protected least significant difference test (PLSD).
For studies involving the comparison of paired samples, statistical
significance was assessed by Student’s (paired) t test. In all cases, p 
0.05 was considered to be indicative of statistical significance.
Results
The use of trkA (SY5Y-TrkA) and mock (SY5Y-ET) transfec-
tants, respectively, of SH-SY5Y human neuroblastoma cells
(Poluha et al., 1995) allowed us to examine the effects of ma-
nipulation of the TrkA/p75 ratio without alteration of the abso-
lute amount of p75 on the cell surface. SY5Y-ET cells express
TrkA and p75 at native levels. SY5Y-TrkA cells express native
levels of p75, and TrkA in 100-fold excess over native levels. The
TrkA/p75 ratio of these cells is 100/100, whereas that of native
SH-SY5Y cells and SY5Y-ET cells is 1/100. The p75 content of
both transfectants is equivalent (Poluha et al., 1995).
NCS Induces Apoptosis in Both SY5Y-ET and SY5Y-
TrkA Cells. Previous studies (Hartsell et al., 1995; Hartsell
et al., 1996) have demonstrated that NCS induces apoptosis
in the parent cell line, SH-SY5Y. Similarly, 48 to 72 h after a
1-h exposure to NCS, both SY5Y-ET and SY5Y-TrkA cells are
seen by light microscopy to shrink, round-up, and detach
from the culture surface in a time- and NCS concentration-
dependent manner (data not shown). Cells of both transfec-
tants also demonstrate apoptotic changes in nuclear config-
uration seen after fluorescent staining (Fig. 1, A-D).
To quantify cell number after NCS treatment (0–20 nM),
cell counts of adherent cells were performed for SY5Y-ET and
SY5Y-TrkA transfectants over an experimental period of 7
days after 1 h of NCS treatment. The effects of NCS on
adherent cell number were concentration-dependent and be-
came apparent on day 3 in both transfectants. NCS was
equipotent for diminution of adherent cell number in the two
transfectants (n  6; data not shown).
In addition, we also examined the apoptotic response of
SY5Y-ET and SY5Y-TrkA cells to NCS treatment (performed
for 1 h on day 0) with 7-AAD staining and flow cytometric
analysis on day 3. As demonstrated in Fig. 1E, a concentra-
tion-dependent increase in the apoptotic fraction, detected as
cells with sub-2N DNA content, was found after NCS treat-
ment. The within-experiment concentration dependence was
robust despite some between-experiment variability of the
absolute incidence of apoptosis at a given NCS concentration.
Flow cytometric analysis also demonstrates the equipotency
of NCS for the two transfectants.
Protective Effects of NGF on NCS-Treated SY5Y-ET
and SY5Y-TrkA Cells. To determine whether NGF can
induce resistance of SY5Y-ET and SY5Y-TrkA cells to NCS-
induced apoptosis, flow cytometric analysis was performed in
the presence of NGF (2 nM) from 24 h before NCS (3 or 10
nM) treatment through the duration of the experiment. As
shown in Fig. 2, incubation with NGF protected both
SY5Y-ET and SY5Y-TrkA cells from NCS-induced apoptosis.
MC192, a p75-Specific NGF Ligand, Protects Low
TrkA/p75 (SY5Y-ET) but not High TrkA/p75 (SY5Y-
TrkA) Cells from NCS-Induced Apoptosis. Previous
work has demonstrated the specificity of MC192 for p75
(Chandler et al., 1984; Barker and Shooter, 1994). MC192
has been shown to synergistically enhance the activity of the
TrkA-specific ligand, 5C3, in much the same way as NGF
binding to p75 enhances NGF signaling through TrkA (Ma-
liartchouk and Saragovi, 1997). We have therefore used
MC192 to determine the effects of ligand binding of p75 alone
in SY5Y-ET and SY5Y-TrkA cells.
Fluorescent nuclear staining suggested that MC192 de-
creased the incidence of condensed nuclei in NCS-treated
SY5Y-ET cells, although it did not alter the incidence of con-
densed nuclei in NCS-treated SY5Y-TrkA cells (data not
shown). Similarly, whereas MC192 increased the EC50 (as de-
fined in Schor et al., 2000) for decrease in adherent cell number
after NCS treatment of SY5Y-ET cells from 5 to 20 nM, it had
no effect on the EC50 of SY5Y-TrkA cells (Fig. 3A). Consistent
with the cell counting results, flow cytometric analysis showed
a differential effect of MC192 upon SY5Y-ET and SY5Y-TrkA
cells (Fig. 3B). MC192 protects SY5Y-ET cells, but not SY5Y-
TrkA cells, from apoptosis induction by NCS.
mAbNGF30, an Anti-NGF Antibody That Renders In-
active the p75 Binding Site of NGF, Protects High
TrkA/p75 (SY5Y-TrkA) but Not Low TrkA/p75 (SY5Y-
ET) Cells from NCS-Induced Apoptosis. We have previ-
ously documented the protection of SH-SY5Y cells, the par-
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ent cells of both transfectants, from the effects of NCS on cell
number by NGF binding to p75 under circumstances when
NGF binding to TrkA was blocked by an engineered, TrkA-
specific mutant NGF (Cortazzo et al., 1996). We have now
used the monoclonal antibody mAbNGF30 to block the p75
binding site of NGF, thereby converting NGF into a ligand
that binds to TrkA but not to p75 (Saragovi et al., 1998). We
have tested the effect of this NGF-NGF30 complex on NCS-
treated SY5Y-ET and SY5Y-TrkA cells. As is shown in Fig. 4,
the NGF-NGF30 complex does not protect SY5Y-ET cells
from the effects of NCS. In contrast, NGF-NGF30 does pro-
tect SY5Y-TrkA cells in the same system. Control treatment
of either transfectant with mAbNGF30, NGF, or NGF-
NGF30 alone (i.e., without NCS) had no effect on apoptosis
prevalence, and mAbNGF30 did not alter the increased prev-
alence of apoptosis seen after NCS treatment (data not
shown). This further suggests that the role of p75 is different
in these two cell lines, despite the fact that both lines express
the same amount of p75.
NF-B Activation Accompanies NGF-Mediated Pro-
tection of SY5Y-ET, but Not SY5Y-TrkA Cells from the
Effects of NCS. The NF-B pathway has been proposed to
be involved in independent (i.e., non–TrkA-dependent) sig-
naling of NGF through p75. We therefore examined the ac-
tivation of this pathway by NGF in SY5Y-ET and SY5Y-TrkA
cells. The difference in signaling by NGF between the two
transfectants was suggested by gel supershift studies of
NF-B activation after incubation of each transfectant with
vehicle or NGF. Treatment of SY5Y-ET cells with NGF (2
nM) for 2 h results in more intense staining of the compo-
nents of NF-B with a radiolabeled specific oligonucleotide
probe (Fig. 5). Both the p65 and p50 components of NF-B
seem to be represented in this staining, as demonstrated by
the displacement and altered staining characteristics of each
in turn in the lanes containing antibodies to each of these
components, respectively. On the other hand, similar treat-
ment of SY5Y-TrkA cells results in no significant change in
the intensity of staining of NF-B with this probe. Note that
both cell lines exhibit some baseline nuclear content of NF-
B, as expected for cells cultured in growth factor- (i.e.,
serum-) containing medium.
Because of the difficulty quantifying gel supershift data
and because the NF-B signaling pathway involves phos-
phorylation of IB- and p65 translocation, we confirmed
these results by examining the phospho- and total IB-
contents (Fig. 6A) and p65 translocation in SY5Y-ET (Fig.
6B) and SY5Y-TrkA (Fig. 6C) cells over time of exposure to
NGF. As demonstrated in Fig. 6A, the cellular content of
phospho-IB- significantly increased over time in SY5Y-ET
cells, whereas the content of IB- remained constant. Con-
sistent with this result, translocation of p65 protein from the
cytoplasm to the nucleus was observed after NGF (2 nM)
treatment of SY5Y-ET cells (Fig. 6B). This phenomenon was
also observed in the case of treatment with NCS (1 h) in the
presence of NGF (Fig. 6D). These results imply that signaling
through an independent p75 receptor and the NF-B path-
way could be an important mechanism by which NGF pro-
tects SY5Y-ET cells from NCS-induced apoptosis. In sharp
contrast, neither phosphorylation of IB- nor translocation
of p65 protein changed significantly during incubation of
SY5Y-TrkA cells with NGF alone (Fig. 6, A and C) or
NCSNGF (Fig. 6E), implying that despite the invariant
content of p75 between these two transfected cell lines, in the
Fig. 1. Nuclear fluorescent staining of SY5Y-ET (A, B) and SY5Y-TrkA (C, D) stained with acridine orange and ethidium bromide to demonstrate
apoptosis induced by NCS treatment. Nonadherent cells were collected, stained, and photographed on day 3 after a 1-h NCS treatment. A and C,
[NCS], 3 nM; B and D, [NCS], 10 nM. Apoptotic cells are distinguished by condensed (white arrows) and fragmented (green arrowheads) chromatin.
(magnification, 1000) E, NCS (0, 1, 3, 5, 10, and 20 nM; 1 h) increases cell death in a dose-dependent manner in both SY5Y-ET and SY5Y-TrkA cells.
Both transfectants were treated with NCS. Pooled adherent and nonadherent cells were harvested, stained with 7-AAD, and analyzed by flow
cytometry. Electronic gates were set for viable and apoptotic cells with 2N to 4N DNA and subnormal DNA content, respectively. Percent apoptosis
observed in a simultaneous vehicle-treated sister culture was subtracted from the respective value obtained in the presence of NCS. Shown is the
cumulative result of five experiments. Error bars on this and all subsequent bar graphs represent the S.D. , p  0.05; , p  0.01; , p  0.001
compared with vehicle-treated cells [one-way ANOVA followed by Fisher’s PLSD test]. Inset, representative histogram (SY5Y-ET cells).
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SY5Y-TrkA line, NGF does not signal through an indepen-
dent, NF-B-linked p75 receptor.
Independent Signaling through p75 in SY5Y-ET
Cells Is Not the Result of Lack of a Critical Threshold
TrkA Content in These Cells; TrkA Signaling Is Com-
petent in SY5Y-ET Cells. From the results we describe
above, it is not possible to distinguish between alteration of
TrkA/p75 ratio and expression of a critical threshold number
of TrkA receptors as the reason for differential signal trans-
duction. It is theoretically possible that signaling through the
TrkA tyrosine phosphorylation pathway requires a critical
number of TrkA receptors and that only independent p75-
mediated signaling was important in protection against ap-
optosis of SY5Y-ET cells because no TrkA-mediated signaling
of NGF occurred. We therefore examined NGF-induced TrkA
phosphorylation in SY5Y-ET and SY5Y-TrkA cells treated
with NGF at a concentration (40 nM) sufficient to saturate
both TrkA and p75. In so doing, we sought to test the hy-
pothesis that, even with low TrkA content, SY5Y-ET cells are
capable of phosphorylating TrkA.
Fig. 7A confirms the differential expression of TrkA in the
two transfectants. Figures 7, B and C, and 8 show that even
when p75 is saturated with NGF and TrkA is present only at
native levels, NGF-mediated TrkA phosphorylation takes
place in both transfectants, and that the relatively low TrkA
expression of SY5Y-ET cells does not preclude such phos-
phorylation.
Fig. 2. Protective effects of NGF (2 nM) on NCS (3 nM, 10 nM; 1 h)
-induced apoptosis in SY5Y-ET (A, C) and SY5Y-TrkA (B, D) cells. Sister
cultures were pretreated with NGF for 24 h, then exposed to NCS for 1 h
in the presence of NGF. NGF was maintained in the culture medium
throughout the duration of the experiment. On day 3 after NCS treat-
ment, the cells were harvested, stained with 7-AAD, and analyzed by flow
cytometry. Percentage of apoptosis observed in a simultaneous vehicle-
treated control was subtracted from the respective NCS- or NCSNGF-
treated sister culture. Each line represents one independent trial (paired
NCS- and NCSNGF-treated samples) of four performed.
Fig. 3. Effects of MC192 on NCS-induced SY5Y transfectant cell death. A,
both SY5Y-ET and SY5Y-TrkA cells were pretreated with 1 nM MC192
for 24 h, then exposed to NCS (1, 3, 5, 10, and 20 nM) for 1 h in the
presence of MC192. Where indicated, MC192 was maintained in the
culture medium throughout the duration of the experiment. Cell counts
are performed at 2 d after NCS treatment. , p  0.05; , p  0.001
(one-way ANOVA followed by PLSD) compared with corresponding group
without MC192. B, both transfectants were treated as described in A.
Flow cytometry was performed on day 3 after NCS treatment as de-
scribed for Fig. 2. Percentage of apoptosis observed in a simultaneous
vehicle-treated control was subtracted from the respective value obtained
in the NCS- or NCSMC192-treated sister culture. , p  0.05 compared
with NCS treatment alone (Student’s t test)
Fig. 4. Effects of blocking p75 binding of NGF on its anti-apoptotic
activity in SY5Y-ET and SY5Y-TrkA cells. Sister cultures of SY5Y-ET
and SY5Y-TrkA cells were treated with all possible combinations of
vehicle, NCS (3 and 10 nM, 1 h, 37°C), NGF (final concentration, 2 nM)
present from 24 h before NCS addition through the termination of the
experiment, and mAbNGF30 (final concentration, 4 nM), as we have
described previously for other antibodies (Cortazzo et al., 1996). Flow
cytometry was performed as described for Fig. 2. NGF alone, mAbNGF30
alone, and NGF  mAbNGF30 had no effect on flow cytometric profiles.
Similarly, mAbNGF30 alone had no effect on change in flow cytometric
profile induced by NCS (data not shown). For both transfectants,
NCSNGF treatment values differ significantly from NCS alone values
[, p  0.05; , p  0.01 (one-way ANOVA followed by PLSD)]. For
SY5Y-ET cells, NGFNCSAb treatment values differ significantly from
NCSNGF treatment values (##, p  0.01; ###, p  0.001), but not from
NCS alone values (p  0.05). For SY5Y-TrkA cells, NGFNCSAb
treatment values do not differ significantly from NCSNGF treatment
values (p  0.05).
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Absence of Independent Signaling through p75 in
SY5Y-TrkA Cells Is Not the Result of Inability of NGF
to Induce Activation of NF-B through p75; p75 Signal-
ing Is Competent in SY5Y-TrkA Cells. NGF, a ligand of
both TrkA and p75, does not induce activation of NF-B in
SY5Y-TrkA cells. This could mean either that p75 does not
function independently when the TrkA/p75 ratio is 100/100
and both p75 and TrkA are bound to NGF, or that p75 is
incapable of independent signaling under any circumstances
in this transfectant. To distinguish between these possibili-
ties, we examined SY5Y-TrkA and SY5Y-ET cells for activa-
tion of NF-B after treatment with MC192, a ligand that
binds to p75 but not to TrkA (Chandler et al., 1984; Barker
and Shooter, 1994). As shown in Fig. 9, in both SY5Y-ET and
SY5Y-TrkA cells, binding of MC192 by p75 results in a time-
dependent increase in cellular levels of phospho-IB-,
whereas levels of actin and IB- remain constant. Binding
of MC192 to p75 therefore activates NF-B in both transfec-
tants. This is not the case for NGF, which suggests that the
inability of NGF to activate NF-B in SY5Y-TrkA cells is
related to its binding to both TrkA and p75 and not to an
innately incompetent pathway through p75 to NF-B activa-
tion in these cells.
In SY5Y-ET cells, p75 Enhances TrkA-Mediated Sig-
naling of NGF, Whereas in SY5Y-TrkA Cells, p75 Does
Not Synergize with TrkA. We also tested the hypothesis
that in SY5Y-TrkA cells, but not SY5Y-ET cells, binding of
NGF to p75 serves to enhance phosphorylation of TrkA re-
sulting from exposure to a single concentration of NGF. This
Fig. 5. Effect of NGF on NF-B activation in SY5Y-ET and SY5Y-TrkA
cells. Gel supershift assays were performed as detailed under Materials
and Methods using oligonucleotides that bind specifically to NF-B. Nu-
clear preparations from all experimental conditions in both transfectants
were simultaneously run on a single gel. Lanes 1 to 6, cells under native
conditions; lanes 7 to 12: cells treated for 2 h with NGF (2 nM). Results
are shown from one representative experiment of two performed. P, probe
alone; 1, SY5Y-ET nuclear prep.  probe; 2, SY5Y-ET nuclear prep. 
anti-p50 antibody  probe; 3, SY5Y-ET nuclear prep.  anti-p65 antibody
 probe; 4, SY5Y-TrkA nuclear prep.  probe; 5, SY5Y-TrkA nuclear
prep.  anti-p50 antibody  probe; 6, SY5Y-TrkA nuclear prep.  anti-
p65 antibody  probe; 7, (SY5Y-ET  NGF) nuclear prep.  probe; 8,
(SY5Y-ET  NGF) nuclear prep.  anti-p50 antibody  probe; 9,
(SY5Y-ET  NGF) nuclear prep.  anti-p65 antibody  probe; 10, (SY5Y-
TrkA  NGF) nuclear prep.  probe; 11, (SY5Y-TrkA  NGF) nuclear
prep.  anti-p50 antibody  probe; 12, (SY5Y-TrkA  NGF) nuclear prep.
 anti-p65 antibody  probe. The open arrows indicate the shifted
position of p50 in lanes including an antibody to this protein. The closed
arrowheads indicate the disappearance of the band for p65 in lanes
including an antibody to this protein. Binding of specific antibody to p65
has previously been shown to alter binding to the oligonucleotide probe
sufficiently to diminish radiographic detection of this protein (Carter et
al., 1996).
Fig. 6. A, effects of NGF on phosphorylation of IB-. Western blotting
was performed to examine SY5Y-ET and SY5Y-TrkA cells for phosphor-
ylation of IB- after NGF exposure (2 nM; 0–6 h). Blots were stripped
and then stained for IB- and -actin as IB- expression and loading
controls, respectively. Plots of optical density were generated using a
Bio-Rad Optiscan optical scanner and normalized to IB- expression.
Intensity of the band for -actin did not change significantly from lane to
lane (data not shown). Results are shown from one representative exper-
iment of three performed. B to E, expression and translocation of p65
protein after NGF (2 nM) treatment in the absence (B and C) and
presence (D and E) of NCS were performed in SY5Y-ET cells (B and D)
and SY5Y-TrkA cells (C and E). Sister cultures of SY5Y-ET and SY5Y-
TrkA cells grown on glass coverslips were incubated for varying lengths
of time with NGF (B and C) or preincubated with NGF for 24 h followed
by 1 h of NCS (3 and 10 nM) treatment in the presence of NGF and
another 24 h of incubation with NGF alone (D and E). The cells were
washed, fixed, blocked, and stained with anti-p65 polyclonal antibody.
Subsequent washing, staining with a fluorescent secondary antibody, and
microscopy were performed as detailed under Materials and Methods.
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was suggested by our finding that the ratio of the optical
densities of the band for phospho-TrkA to that for TrkA
peaks at 1.25-fold above control levels after 30-min incuba-
tion with NGF in SY5Y-ET cells, whereas the analogous ratio
peaks at 3.75-fold of control levels after 5-min incubation
with NGF and remains close to this level for at least 2 h in
SY5Y-TrkA cells (data not shown). This is consistent with
synergistic enhancement of TrkA activity by p75 in cells with
a high TrkA/p75 ratio, as has been seen previously in other
cell systems (Maliartchouk and Saragovi, 1997; Ross et al.,
1998; Rabizadeh et al., 1999).
In confirmation of this observation, the p75 ligand MC192
(2 nM) is itself without effect on SY5Y-TrkA cells but affords
synergistic enhancement of the antiapoptotic effect of the
TrkA ligand 5C3 on these cells. Conversely, 5C3 (5 nM) alone
is without effect on SY5Y-ET cells, and coincubation with
5C3 and MC192 does not alter the antiapoptotic effect of
MC192 on these cells (Fig. 10). These results underscore the
differential signaling capacity of NGF receptors in the two
transfectants, and demonstrate the different roles played by
p75 in SY5Y-TrkA and SY5Y-ET cells.
Discussion
Neurotrophins have been implicated in positive and negative
modulation of the susceptibility of neural tumors to chemother-
apeutic agents (Cortazzo et al., 1996; Kim et al., 1999; Schor,
1999). NGF, the first neurotrophin described, has been found to
Fig. 7. A, differential TrkA receptor protein expression in SY5Y-ET and
SY5Y-TrkA cells. Immunofluorescent staining for TrkA was performed on
the native transfectants. B and C, effects of NGF on phosphorylation of
TrkA are shown for SY5Y-ET (B) and SY5Y-TrkA (C) cells. Sister cultures
of SY5Y-ET and SY5Y-TrkA cells were incubated for varying lengths of
time with NGF (40 nM). Results for t  0 (control) are denoted as “Cont”.
The TrkA and phospho-TrkA (p-TrkA) contents of lysates of these cells
were determined by Western blotting as described under Materials and
Methods. In the case of each transfectant, the same blot was stained with
an antibody to TrkA, stripped, and subsequently stained with an anti-
body to p-TrkA. The notation to the left of each blot indicates the running
position of a 140 kD TrkA standard on the same gel. A representative set
of results for one experiment of four performed with SY5Y-TrkA cells and
three performed with SY5Y-ET cells is shown.
Fig. 8. Immunofluorescent staining for phospho-TrkA in SY5Y-ET and
SY5Y-TrkA cells treated with NGF (40 nM). Sister cultures of SY5Y-ET
and SY5Y-TrkA cells grown on glass coverslips were incubated for vary-
ing lengths of time with NGF and then stained with an antibody to
phospho-TrkA. Staining with a fluorescent secondary antibody and sub-
sequent microscopy were performed as detailed under Materials and
Methods. Panels labeled “0 min” were treated with vehicle only and
stained immediately thereafter.
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variably induce or prevent apoptosis of normal and neoplastic
neural cells, depending upon the method by which apoptosis is
induced and which of the two known NGF receptors (p75 or
TrkA) is involved in mediating the response to NGF (Bredesen
and Rabizadeh, 1997; Bredesen et al., 1998).
In addition, previous studies have demonstrated the mul-
tiple roles of the p75 receptor (Frade and Barde, 1998) and
have suggested that its predominant role varies from cell
type to cell type (Cortazzo et al., 1996). What determines the
function of p75 in different cell types or in the same cell at
different times in its development remaines unclear (Fundin
et al., 1997). Several studies have indicated that p75 binding
to TrkA, TrkB, or TrkC enhances the affinity of the respec-
tive Trk for its corresponding neurotrophin (Hempstead et
al., 1991; Bredesen and Rabizadeh, 1997; Ryden et al., 1997;
Ross et al., 1998; Brennan et al., 1999). Recently, it has been
reported that a complex consisting of TRAF6 and atypical
protein kinase C-interacting protein (p62) could serve as a
bridge between p75 and TrkA signaling (Wooten et al., 2001).
This interaction is almost certainly initiated by the physical
proximity of the two receptors to one another (Huber and
Chao, 1995; Gargano et al., 1997; Bibel et al., 1999). Some
authors have hypothesized that the direct interaction of p75
with TrkA requires that the TrkA/p75 ratio be no smaller
than 1/10 (Verdi et al., 1994; Greene and Kaplan, 1995).
However, most of the studies performed to test this hypoth-
esis compare the response to NGF of different cell lines that
undoubtedly differ in characteristics other than just the
TrkA/p75 ratio. Furthermore, none of these studies approach
the question of what, if anything, p75 does in cells where a
physical or functional TrkA-p75 interaction is not apparent.
The present study demonstrates that NGF decreases NCS-
induced apoptosis in both SY5Y-ET and SY5Y-TrkA cells
(Fig. 2). This neuroprotective effect of NGF is mediated by
p75 in SY5Y-ET cells and by TrkA in SY5Y-TrkA cells. This
conclusion is based on the following observations. First,
monoclonal antibody MC192, a p75-specific NGF ligand, se-
lectively protects SY5Y-ET cells, but not SY5Y-TrkA cells,
from NCS-induced apoptosis (Fig. 3). Second, mAbNGF30,
which occupies and inactivates the p75 binding site of NGF,
selectively abolishes the protective effects of NGF on NCS-
treated SY5Y-ET cells but not NCS-treated SY5Y-TrkA cells
(Fig. 4). Third, although p75–NF-B signaling is intact in
both transfectants (Fig. 9), NGF induces such signaling only
in SY5Y-ET cells (Figs. 5 and 6, A, B, and D), and not in
SY5Y-TrkA cells (Figs. 5 and 6, A, C, and E). Thus, although
Fig. 9. Effects of monoclonal antibody MC192 on cellular content of phos-
phorylated IB-. Western blotting was performed to examine SY5Y-ET and
SY5Y-TrkA cells for phosphorylated IB- after MC192 exposure (2 nM;
0–4 h). Plots of optical density were generated using a Bio-Rad Optiscan
optical scanner. Each blot was stripped and stained for -actin and IB- as
a loading control and control for IB- expression, respectively. Results
shown are from one representative experiment of two performed.
Fig. 10. The synergistic protective effects of 5C3 and MC192 on NCS-induced cell death in SY5Y-TrkA but not SY5Y-ET cells. Sister cultures were pretreated
with 5C3 (5 nM) and/or MC192 (2 nM) for 24 h, then exposed to 10 nM NCS for 1 h in the presence of 5C3 and/or MC192. MC192 and 5C3 were left in the
medium for the duration of the experiment. Results are expressed as relative incidence of apoptosis with apoptosis incidence in a simultaneous control
sample set at 1. This represents the fold-increase in apoptosis after treatment relative to control conditions. , p  0.05; , p  0.01 compared with NCS
alone; #, p  0.05 protective effect of both ligands in coincubation compared with either ligand alone (one-way ANOVA followed by PLSD)
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the absolute p75 content is the same in both transfectants,
the role of p75 signaling in the neuroprotective effects of NGF
differs between them. The present studies are consistent
with the study by Twiss et al. (1998), who reported that not
only the presence of p75 but also the p75/TrkA ratio deter-
mines cellular responsiveness to NGF. Although there is
ample evidence that changes in ligand concentration or avail-
ability that lead to alterations in receptor occupancy rate can
alter the predominant signal transduction pathway activated
by that ligand (Shimizu and Gurdon, 1999), no prior studies
have shown directly that heterologous receptor ratio deter-
mines signaling by a single common ligand.
Many recent studies have demonstrated the existence of an
independent function of p75 (Carter et al., 1996; Cortazzo et
al., 1996; Brann et al., 1999; Coulson et al., 1999; Yamashita
et al., 1999; Huang et al., 2000). The exact independent
function of p75 seems to depend on whether NGF is bound to
it (Rabizadeh et al., 1993; Huang et al., 2000). As a “naked”
receptor, p75 seems in some cells to function as a mediator of
apoptosis. In contrast, the binding of NGF to p75 prevents
apoptosis induction in these lines (Rabizadeh et al., 1993;
Cortazzo et al., 1996); p75 has therefore been said to induce
“neurotrophin dependence” in cells (Bredesen et al., 1998). A
number of studies in other cell types have demonstrated the
apoptosis-inducing effect of NGF binding to p75 (Kuner and
Hertel, 1998; Sedel et al., 1999). The present experiments
differ from these studies in that we use an antimitotic, DNA-
cleaving agent in the presence of serum, rather than serum
deprivation or NGF exposure itself, to induce cell death.
Apoptosis in this model is not itself p75-dependent, as evi-
denced by the absence of effect of NGF, MC192, or 5C3 alone
(i.e., in the absence of NCS) on SY5Y-ET or SY5Y-TrkA cells.
Binding of NGF to p75 protects these cells from apoptosis
induced by the enediyne chemotherapeutic agent, NCS. This
protection may be reflective of potential resistance to chemo-
therapy, and could therefore presage the existence of residual
tumor after treatment. Because these neoplastic cells are
mitotically active, even small numbers of chemoresistant
cells could be biologically and medically significant.
From the signal transduction standpoint, TrkA is the start-
ing point for a tyrosine kinase pathway that clearly mediates
the differentiative and trophic functions of NGF. Many of the
intermediate steps in the pathway from TrkA binding of NGF
to the induction of neurite outgrowth have been identified
(Cordon-Cardo et al., 1991; Kaplan et al., 1991; Kremer et al.,
1991; Ohmichi et al., 1991; Saltiel and Ohmichi, 1993). More
recently, an antiapoptosis function and pathway for TrkA
have been described as well (Pincelli et al., 1997; Garcia
Valenzuela and Sharma, 1998).
Other studies have suggested that NF-B activation is
associated with cell survival in some systems (Beg and Bal-
timore, 1996; Liu et al., 1996; Van Antwerp et al., 1996;
Wang et al., 1996). The signal transduction pathways respon-
sible for this association are only recently being elucidated.
NF-B is composed of two subunits (p65 and p50) and exists
in a complex with an inhibitory protein, termed IB, in rest-
ing cells (Nagata, 1997). It has been suggested that ligand-
induced trimerization of tumor necrosis factor (TNF) results
in the recruitment of the death domain adaptor protein
TRADD, which in turn recruits and interacts with receptor
interaction protein (Ashkenazi and Dixit, 1998). Overexpres-
sion of receptor interaction protein activates NF-B–induc-
ing kinase, which in turn activates IB kinase complex
(IKK). Upon phosphorylation by IKK, IB becomes ubiquiti-
nated and degraded by proteosome complexes (Zandi et al.,
1997). Once free of this inhibitor, NF-B dimerizes and be-
comes an active transcription factor that translocates to the
nucleus and activates transcription of NF-B–responsive
genes (Ashkenazi and Dixit, 1998). The low-affinity NGF
receptor, p75, is a member of the TNF receptor family, and
there is evidence to support the notion that activation and
translocation of NF-B are steps in the signaling cascade
initiated by NGF binding to p75 (Carter et al., 1996).
In the present study, we demonstrated that NGF induces
phosphorylation of IB- in SY5Y-ET cells, but not in SY5Y-
TrkA cells (Fig. 6A). Furthermore, NGF induces the translo-
cation of p65 from the cytoplasm to the nucleus of SY5Y-ET,
but not SY5Y-TrkA, cells (Fig. 6, B-E). These findings, taken
together with the effects of selective TrkA or p75 agonists in
this system, support the notion that NGF protects against
NCS-induced apoptosis through the p75-NF-B signaling
pathway in SY5Y-ET cells, and through a TrkA tyrosine
phosphorylation pathway in SY5Y-TrkA cells.
These findings suggest that in cell lines and at stages of in
vivo development in which p75 is in overabundance relative to
TrkA, p75 serves an independent function, whereas a TrkA/p75
ratio closer to 100/100 implies enhancement of the TrkA-medi-
ated functions of NGF by p75. Given the very wide tissue
expression profile of p75 (Wheeler et al., 1998; Guate et al.,
1999; Lara et al., 2000), these relationships are likely to have
implications in both neural and non-neural tissues and patho-
logical states (Labouyrie et al., 1997; Brann et al., 1999; Ha-
manoue et al., 1999; Hannila and Kawaja, 1999; Guate et al.,
1999; Lara et al., 2000; Sortino et al., 2000). Whether NGF
receptors can serve as a prototype for other homo- and het-
erodimeric receptors remains to be seen, particularly with re-
gard to the mechanism by which receptor pairing is determined.
Furthermore, additional studies will determine the generaliz-
ability to other chemotherapeutic agents of the effects of NGF
on susceptibility to enediyne-induced apoptosis.
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